You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Revenues during the quarter were $716.3 million, beating Wall Street estimates, while full year 2019 revenues totaled $2.41 billion.
Gladstone Institutes researchers will use proteomic, genomic, and gene-altering approaches to investigate apoe4 toxicity as part of a five-year project.
While overall revenues and net income were up, analytical instruments revenues decreased 3 percent in Q4, and 2 percent organically.
A federal judge granted IonPath's motion to dismiss portions of Fluidigm's suit but claims of direct infringement were untouched and will proceed.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
A survey asking researchers for their thoughts on the key developments in the field turned up applications ranging from clinical to structural.
Data privacy has been an issue in genomics for some time, but new regulations and improved technology could force proteomics to confront it, as well.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
According to its developers, the software allows for the quantification several hundred proteins in five-minute DIA analyses of undepleted plasma.
Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
PTC Therapeutics is developing a gene therapy for the rare genetic disease AADC deficiency, which impacts the production of two key neurotransmitters.
The company said it will use the funds to support development of its structure for lossless ion manipulation (SLIM) ion mobility separations technology.
The researchers suggested that the system's combination of speed and high coverage could enable new applications within the imaging mass spec space.
Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.
Revenues rose to $521.1 million from $466.6 million in Q3 2018, beating the consensus Wall Street estimate of $496.7 million.
Waters posted revenues of $577.3 million, short of the average Wall Street estimate of $588.9 million, as soft US pharma sales negatively impacted businesses.
Researchers measured proteins produced by 193 deletions in 136 CRISPR-deleted genes and found residual protein expression in roughly one-third of these cases.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.